Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 15/20 | 0.55 |
| ▸ | AKT2 | P31751 | 10/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.53 |
| ▸ | AKT3 | Q9Y243 | 4/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | JAK3 | P52333 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 4/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3651970 | 0.89 | AKT1 (0.55) | AKT1AKT2ROCK2AKT3KCNH2 | |
| SCHEMBL391354 | 0.88 | AKT1 (0.51) | AKT1AKT2ROCK2AKT3KCNH2 | |
| SCHEMBL20544762 | 0.79 | AKT1 (0.60) | AKT1AKT2ROCK2AKT3KCNH2 | |
| SCHEMBL20545097 | 0.78 | AKT1 (0.79) | AKT1AKT2ROCK2AKT3KCNH2 | |
| SCHEMBL20544959 | 0.78 | AKT1 (0.57) | AKT1AKT2ROCK2AKT3KCNH2 | |
| SCHEMBL3650884 | 0.78 | AKT1 (0.52) | AKT1AKT2ROCK2AKT3KCNH2 | |
| SCHEMBL3488749 | 0.77 | AKT1 (0.53) | AKT1AKT2ROCK2AKT3KCNH2 | |
| SCHEMBL3659051 | 0.77 | AKT1 (0.51) | AKT1AKT2ROCK2AKT3KCNH2 | |
| SCHEMBL3655526 | 0.77 | AKT1 (0.51) | AKT1AKT2ROCK2AKT3KCNH2 | |
| SCHEMBL3656369 | 0.77 | AKT2 (0.56) | AKT1AKT2ROCK2AKT3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180312516-A1 | Protein Kinase B Inhibitors | ASTRAZENECA AB (SE) | 2018-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312516-A1 | Protein Kinase B Inhibitors | PRKAR2B, PRKCB, AKT1 | AKT1 3/4885AKT2 4/4885ROCK2 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.